Table 1.
Socio-demographic and clinical characteristics by Patient Oriented Eczema Measure severity.
| Variable | Disease severity by Patient Oriented Eczema Measure (POEM) |
|||
|---|---|---|---|---|
| Mild (n=17) | Moderate (n=23) | Severe (n=21) | P-value | |
| Male*, n (%) | 6 (35.3) | 12 (52.2) | 13 (61.9) | 0.26 |
| Age, mean (SD) | 11.7 (3.8) | 11.1 (4.2) | 12.2 (3.7) | 0.66 |
| Race, n (%) | 0.26 | |||
| Asian | 4 (23.5) | 3 (13.0) | 1 (4.8) | |
| Black | 0 (0.0) | 5 (21.7) | 6 (28.6) | |
| White | 9 (52.9) | 9 (39.1) | 10 (47.6) | |
| Other | 4 (23.5) | 6 (26.1) | 4 (19.0) | |
| Latino, n (%) | 6 (35.3) | 5 (21.7) | 7 (33.3) | 0.58 |
|
| ||||
| POEM, mean (SD) | 3.9 (2.1) | 11.7 (2.9) | 21.8 (3.0) | <0.01 |
| CDLQI, mean (SD) (n=43) | 2.0 (1.6) | 4.2 (3.0) | 8.7 (5.7) | <0.01 |
| NRS, mean (SD) (n=59) | 2.2 (1.9) | 4.8 (2.7) | 6.2 (2.4) | <0.01 |
|
| ||||
| Asthma, n (%) | 11 (64.7) | 14 (60.9) | 14 (66.7) | 0.92 |
| Allergic Rhinitis, n (%) | 16 (94.1) | 18 (78.3) | 17 (81.0) | 0.38 |
| Food Allergy, n (%) | 11 (64.7) | 21 (91.3) | 15 (71.4) | 0.11 |
| ADHD, n (%) | 1 (5.9) | 2 (8.7) | 2 (9.5) | 0.92 |
| Other Sleep Diagnosis, n (%)** | 0 (0.0) | 0 (0.0) | 2 (9.5) | 0.14 |
|
| ||||
| Therapies during the study | ||||
| Sedating Antihistamine, n (%) | 1 (5.9) | 3 (13.0) | 8 (38.1) | 0.03 |
| Topical corticosteroid, n (%) | 12 (70.6) | 16 (69.6) | 20 (95.2) | 0.07 |
| Systemic immunosuppressant,*** n (%) | 2 (11.8) | 4 (17.4) | 5 (23.8) | 0.63 |
|
| ||||
| Objective Sleep | ||||
| Sleep efficiency %, mean (SD) | 84.2 (3.8) | 81.8 (6.1) | 80.0 (9.0) | 0.18 |
| Sleep onset latency minutes, mean (SD) | 9.4 (5.4) | 14.8 (12.1) | 17.0 (17.0) | 0.19 |
| Wake After Sleep Onset (WASO) minutes, mean (SD) | 67.6 (16.6) | 77.7 (29.1) | 88.8 (53.3) | 0.22 |
| Bed time, mean hh:mm (SD) | 23:00 (2:05) | 22:40 (1:06) | 23:08 (1:32) | 0.60 |
| Wake time, mean hh:mm (SD) | 8:00 (1:10) | 7:46 (0:45) | 8:02 (1:47) | 0.76 |
| Total Sleep Time hh:mm, mean (SD) | 7:35 (1:09) | 7:25 (0:57) | 7:02 (0:46) | 0.19 |
|
| ||||
| Parent-Proxy-Reported Sleep (%) | ||||
| Sleep Disturbance | 55.7 (7.5) | 59.8 (10.8) | 67.1 (9.5) | <0.01 |
| Sleep-Related Impairment | 52.6 (11.8) | 57.4 (7.8) | 62.1 (12.6) | 0.03 |
| Epworth Sleepiness Scale (n=59) | 6.8 (4.9) | 7.6 (3.5) | 8.1 (4.5) | 0.64 |
|
| ||||
| Patient Reported Sleep (n=45), n (%) | ||||
| Sleep Disturbance | 51.2 (9.3) | 55.5 (7.3) | 61.1 (10.3) | 0.02 |
| Sleep-Related Impairment | 49.3 (10.1) | 53.0 (8.9) | 57.8 (9.3) | 0.06 |
*
n=61 unless otherwise noted
**
Sleep walking and snoring
***
systemic immunosuppressants, methotrexate (1 mild, 2 moderate, 3 severe), mycophenolate mofetil (2 moderate), cyclosporine (1 mild, 1 severe), dupilumab (1 severe)
Bold P-values indicate statistically significant at P<0.05
SD=standard deviation; CDLQI=Children’s Dermatology Life Quality Index; NRS=Numerical Rating Scale